Global X Genomics & Biotechnology UCITS ETF USD Acc | GNOMRegister to Unlock Ratings |
Performance History | 31/08/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | -29.3 | -11.1 | -7.1 | |
+/-Cat | - | - | -24.6 | -8.0 | -14.6 | |
+/-B’mrk | - | - | -35.1 | -8.6 | -20.7 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
Closing Price 27/09/2024 | USD 7.91 | |
Day Change | 1.89% | |
Morningstar Category™ | Sector Equity Healthcare | |
Volume | 2002 | |
Exchange | LONDON STOCK EXCHANGE, THE | |
ISIN | IE00BM8R0N95 | |
Fund Size (Mil) 30/09/2022 | USD 6.35 | |
Share Class Size (Mil) 27/09/2024 | USD 6.13 | |
Ongoing Charge 04/09/2023 | 0.50% |
Investment Objective: Global X Genomics & Biotechnology UCITS ETF USD Acc | GNOM |
The investment objective of the Fund is to provide investment results that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index (the “Index”). |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
- - | ||
Inception Date 02/11/2021 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
Solactive Genomics v2 USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Global X Genomics & Biotechnology UCITS ETF USD Acc | GNOM | 26/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Alnylam Pharmaceuticals Inc | Healthcare | 6.93 |
Avidity Biosciences Inc Ordinary... | Healthcare | 5.39 |
Natera Inc | Healthcare | 4.90 |
BioNTech SE ADR | Healthcare | 4.84 |
Ultragenyx Pharmaceutical Inc | Healthcare | 4.52 |
Increase Decrease New since last portfolio | ||
Global X Genomics & Biotechnology UCITS ETF USD Acc | GNOM |